Fingolimod (Fingolimod HCl) Patent Expiration, LOE Window & CMS Spending

Fingolimod (Fingolimod HCl) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 15 AB generics, $65.3M 2024 CMS Part D & Medicaid spend, and $6,607 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors15
2024 CMS Total Public Spend$65.3M
2024 Medicare Part D Spend$54.6M
2024 Medicaid Spend$10.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($6,607 intro WAC)